Bioequivalence Study of an Amoxicillin-Clavulanic

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to confirm if two formulations of amoxicillin and clavulanic acid (suspension) are bioequivalent. Test product was AUGMENTIN 12H (400 mg Amoxicillin and 57 mg Clavulanic acid/ 5 ml; Glaxo Wellcome France) and reference product AUGMENTIN 12H (400 mg Amoxicillin and 57 mg Clavulanic acid/ 5 ml; GlaxoSmithKline Mexico). The single dosage was 10 ml of suspension. The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions. The population was composed of 35 healthy volunteers, both genders, adults between 18-50 years. The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.

Official Title
-----------------
Bioequivalence Study of an Amoxicillin-Clavulanic Acid Suspension Preparation. Cross-over, Randomized, Single Dose, Two Treatments, Two Periods and Two Sequences Trial in Fasting Conditions

Conditions
-----------------
Infections, Respiratory Tract

Intervention / Treatment
-----------------
* Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml
* Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both genders. Ages between 18 and 45 years old. BMI (Body Mass Index) between 20 to 26 kg/m2. Anti-doping tests negative results. Females with negative pregnancy tests Clinical biochemical test values: Hematic Biometry, Urine Analysis, Biochemical Profile: (Glucose, Ureic Nitrogen, Urea, Creatinine, Uric Acid, Cholesterol, Triglycerides, Total Proteins, Albumin, Globulin, Bilirubin (total, indirect and direct), Alkaline Phosphatase, Lactic Dehydrogenase, AST, ALT, Calcium, Phosphorus, Sodium, Potassium, Chlorine and Iron), Ac VIH, AgsHB and RPR (luetic test), must fall within an interval between minimum and maximum values in connection to said tests accepted values. Normal Electrocardiogram and Chest X-rays. In exception cases, accepted may be a candidate for which any previously mentioned test is exceeded regarding considered valid maximum and minimum accepted normal values, as long as it involves an isolated value and there are no other manifestations which could allow assuming that a given value is related to a disease or is remnant of another. These cases must be approved by clinical area and declared as Non-clinically significant. - Exclusion Criteria: Biochemistry, Electrocardiographic Radiological Anomalies; Anti-doping tests positive results, Positive results regarding RPR; VIH and AgsHB tests. Personal or family history of allergy to medication in question. Having any kind of allergy, since these persons are in higher risk of suffering from medicamentous allergy. Tobacco use. Recreational drug use. Persons undergoing any medical treatment. Existence of concurrent or intercurrent disease. Existence of justified doubt regarding questionnaire answers truthfulness. Having participated in bioequivalence or bioavailability studies or having donated blood 2 months before the study. Presence of clinically important gastrointestinal diseases or malabsorption history during the last year. Presence of a medical condition requiring regular medication (with prescription or over-the- counter medication) with systemic absorption. Narcotics or alcohol addiction history requiring treatment. Finally, excluded will be all those volunteers not meeting that established in Mexican Official Standard NOM-177-SSA1-1998. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A(reference)/B(test)<br>initial administration of reference and cross-over to test | Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml<br>* Reference product<br>* Other names: AUGMENTIN 12H suspension GlaxoSmithKline Mexico;Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml<br>* Test product<br>* Other names: AUGMENTIN 12H suspension GlaxoWellcome Production France;|
| Experimental: B(test)/A(reference)<br>initial administration of test and cross-over to reference | Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml<br>* Reference product<br>* Other names: AUGMENTIN 12H suspension GlaxoSmithKline Mexico;Drug: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml<br>* Test product<br>* Other names: AUGMENTIN 12H suspension GlaxoWellcome Production France;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak Plasma Concentration (CMAX) of Amoxicillin-Clavulanic Acid | Pharmacokinetics | 0.0, 0.16, 0.33, 0.66, 1.0, 1.25, 1.5, 1.75, 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 5.0, 6.0, and 8.0 postdosage | 
| Area under the plasma concentration versus time curve (AUC) of Amoxicillin-Clavulanic Acid | Pharmacokinetics | 0.0, 0.16, 0.33, 0.66, 1.0, 1.25, 1.5, 1.75, 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 5.0, 6.0, and 8.0 postdosage | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mexico, Respiratory infections, Amoxicillin-Clavulanic Acid, Bioequivalence